MedTrace Logo

Antimicrobial Stewardship Program for Clostridium Difficile Infection.

NCT02951481 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 403

Last updated 2022-04-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether a bundle of measures specifically designed for patients with ICD and applied by and Infectious Diseases expert during a year period (2017) will improve the prognosis and reduce the rate of recurrence, compared with the baseline phase (2015) in which no intervention was made.

Conditions

  • Clostridium Difficile
  • Enterocolitis, Pseudomembranous

Interventions

BEHAVIORAL

Systematic evaluation by an ID expert.

Specific "bundle" of measures: 1. Systematic evaluation of all patients diagnosed with CDI by an Infectious Disease expert To ensure compliance with clinical practice guidelines about specific treatment for CDI, depending on the severity of the episode and the existence of previous episodes and to optimize concomitant antibiotic therapy ("antimicrobial stewardship"). 2. To ensure appropriate monitoring during the period of greatest risk of relapse in order to reduce as far as possible, the number of relapses. Personalized assistance by telephone or by email for early consultation in case of recurrence of symptoms or need for a new antibiotic course.

Sponsors & Collaborators

  • Hospital Universitario 12 de Octubre

    collaborator OTHER

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • José María Aguado García, MD, PhD

    lead OTHER

Principal Investigators

  • Jose María Aguado, MD. PhD · University Hospital 12 de Octubre. Head of Infectious Disease Unit.

Eligibility

Min Age
18 Years
Max Age
110 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-15
Primary Completion
2017-12-15
Completion
2017-12-15

Countries

  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02951481 on ClinicalTrials.gov